Results 61 to 70 of about 3,523 (219)

Letermovir use for cytomegalovirus prophylaxis following lung transplantation: A single-center review

JHLT Open
Background: Cytomegalovirus (CMV) remains a major cause of infection following solid organ transplant and valganciclovir prophylaxis is the standard of care. However, valganciclovir-associated myelosuppression limits its tolerability and can require dose
Alyssa K. Mezochow, MD, MSc, Kevin D. He, MD, Kathryn Whitaker, MD, Emily Blumberg, MD, Maria M. Crespo, MD, Andrew Courtwright, MD, PhD   +5 more
doaj   +1 more source

Consideration of quality of life in the health technology assessments of rare disease treatments [PDF]

, 2021
Objectives Challenges with patient-reported outcome (PRO) evidence and health state utility values (HSUVs) in rare diseases exist due to small, heterogeneous populations, lack of disease knowledge and early onset. To better incorporate quality of life (
Drummond, Michael, Facey, Karen, Meregaglia, Michela, Nicod, Elena, Upadhyaya, Sheela, Whittal, Amanda   +5 more
core   +1 more source

Current Perspectives on the Management of Herpesvirus Infections in Solid Organ Transplant Recipients [PDF]

, 2023
Solid organ transplant recipients (SOTRs) are at high risk of human herpesvirus (HHV)-related morbidity and mortality due to the use of immunosuppressive therapy.
Baan, Carla C., den Hoed, Caroline M., Hoek, Rogier A.S., Kho, Marcia M.L., Malahe, S. Reshwan K., Manintveld, Olivier C., van Kampen, Jeroen J.A., Verjans, Georges M.G.M.   +7 more
core   +2 more sources

Clinical next-generation sequencing assay combining full-length gene amplification and shotgun sequencing for the detection of CMV drug resistance mutations [PDF]

, 2023
Cytomegalovirus (CMV) causes severe systemic and tissue-invasive disease in immunocompromised patients, particularly solid organ and hematopoietic stem cell transplant recipients.
Caldera, JR, Cerón, Stacey, Chan, June L, Garner, Omai B, Gray, Hannah K, von Bredow, Benjamin, Yang, Shangxin   +6 more
core   +1 more source

Hinge Region in DNA Packaging Terminase pUL15 of Herpes Simplex Virus: A Potential Allosteric Target for Antiviral Drugs [PDF]

, 2019
Approximately 80% of adults are infected with a member of the herpesviridae family. Herpesviruses establish life-long latent infections within neurons, which may reactivate into lytic infections due to stress or immune suppression.
Coghill, Lyndon M., Naderi, Misagh, Rothschild, J. Ainsley, Thaljeh, Lana F.   +3 more
core   +5 more sources

Letermovir Administration to Prevent Cytomegalovirus Reactivation Is the Potential Risk of Chronic Graft-Versus-Host Disease in Patients Who Received Haploidentical Stem-Cell Transplantation With Post-Transplant Cyclophosphamide

Frontiers in Oncology, 2021
The prevention of chronic graft-versus-host disease (cGVHD) is important for recipients of hematopoietic stem-cell transplantation (HSCT). As one of the etiologies, the relationship between early T-cell recovery and subsequent cGVHD development has been ...
Toshiki Terao, Ken-ichi Matsuoka, Kentaro Narita, Takafumi Tsushima, Satoshi Yuyama, Ayumi Kuzume, Rikako Tabata, Daisuke Miura, Masami Takeuchi, Kosei Matsue   +9 more
doaj   +1 more source

Unraveling Cytomegalovirus Drug Resistance in Transplant Patients by Targeting Deep Sequencing

Journal of Medical Virology, Volume 98, Issue 1, January 2026.
ABSTRACT Drug‐resistant cytomegalovirus (CMV) poses a major clinical challenge in transplant recipients, leading to treatment failure and increased morbidity. This study applied a next‐generation sequencing (NGS) approach to identify antiviral resistance mutations (ARMs) in 71 samples from 68 CMV‐positive patients who had undergone hematopoietic stem ...
Salvador Alemán, Juan Camacho, Vanessa Recio, Estrella Ruiz, Pilar Zamarrón, Jorge Anel, Montserrat Enjuto, David Tarragó   +7 more
wiley   +1 more source

HCMV Antivirals and Strategies to Target the Latent Reservoir. [PDF]

, 2021
Human cytomegalovirus (HCMV) is a ubiquitous human herpesvirus. In healthy people, primary infection is generally asymptomatic, and the virus can go on to establish lifelong latency in cells of the myeloid lineage.
Perera, Marianne R, Sinclair, John H, Wills, Mark R   +2 more
core   +2 more sources

Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization

European Journal of Haematology, Volume 116, Issue 1, Page 14-22, January 2026.
ABSTRACT Background Herpes zoster (HZ), resulting from reactivation of latent varicella‐zoster virus (VZV), imposes a significant burden on immunocompromised patients, particularly those with hematological malignancies and recipients of hematopoietic stem cell transplants (HSCT).
Enrica Antonia Martino, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Santino Caserta, Francesco Mendicino, Fortunato Morabito, Massimo Gentile   +10 more
wiley   +1 more source

Letermovir Prophylaxis for Cytomegalovirus [PDF]

New England Journal of Medicine, 2018
Marty and colleagues (Dec. 21 issue)1 found that letermovir prophylaxis after hematopoietic-cell transplantation resulted in a lower risk of clinically significant cytomegalovirus (CMV) infection than placebo. This trial shows that a prophylactic agent can provide meaningful benefit after hematopoietic-cell transplantation, without considerable ...
L'Huillier, Arnaud, Humar, Atul, Kumar, Deepali   +2 more
openaire   +7 more sources